# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Outperform and maintains $6 pr...
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate o...
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM CentralWhite Paper: The Potential o...
- SEC Filing
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments fo...
Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024Key Proof-of-Concept Resu...
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate o...
Craig-Hallum analyst Alexander Nowak assumes DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and announces Price Targ...